)
Visual
test
Dimerix
Dimerix (DXB) investor relations material
Dimerix Q2 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 TU earnings summary28 Jan, 2026
Executive summary
Completed target recruitment of 286 adult patients for the ACTION3 Phase 3 trial in FSGS kidney disease, with pediatric recruitment ongoing as an independent cohort.
Announced successful data analysis from the PARASOL collaboration, supporting the use of proteinuria endpoints for regulatory approval.
Received FDA input confirming proteinuria reduction as a suitable primary endpoint for traditional approval, with eGFR as a secondary endpoint.
7th successful Independent Data Monitoring Committee review of ACTION3 completed.
BioMarin announced intention to acquire US partner Amicus Therapeutics.
CEO awarded 'CEO of the Year' by Biotech Daily.
Financial highlights
Cash position at 31 December 2025 was AU$38.5 million, down from AU$49.2 million at 30 September 2025.
Net operating cash outflows for the December quarter were AU$11.1 million, primarily related to clinical trial and R&D expenses.
Estimated 3.5 quarters of funding available based on current cash burn.
Aggregate payments to related parties for the quarter totaled AU$183,000.
Outlook and guidance
Well positioned to fund ongoing operations and the ACTION3 Phase 3 trial, with continued focus on licensing opportunities in unlicensed territories.
Update on next steps for the ACTION3 trial expected in early 2026 following further FDA feedback.
Detail Q4 operating cash outflow drivers.
What is the next FDA-related ACTION3 milestone?
Explain the OLE study's strategic importance.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- BN4
Net profit up 39% in new model, record infrastructure earnings, and 38% higher dividends. - HEXT
CY25 revenue up 7.6% YoY, Q4 at $389M, with strong deal wins and AI-driven growth ahead. - 6723
Strong AI and industrial demand drive results; timing business sold for $3B; inventory targets raised. - 4902
Operating profit rebounded sharply on cost controls and gains, despite lower revenue. - 032640
Net profit surged 61.9% YoY on strong wireless, broadband, and AIDC growth. - S68
Record revenue, robust segment growth, and strong IPO pipeline drive positive outlook. - 6417
Strong pachinko sales drove revenue growth, with major treasury stock cancellation planned. - BPT
H1 FY26 revenue hit $1B, with strong gas prices and LNG cargoes offsetting lower production. - CPAY
Record 2025 results and 2026 outlook driven by strong segment growth and capital deployment. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand.
Next Dimerix earnings date
H1 202624 Feb, 2026
Dimerix
Next Dimerix earnings date
H1 202624 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Dimerix Limited is an Australian biopharmaceutical company focused on developing new therapies for rare and progressive diseases, particularly kidney and inflammatory diseases. The company’s lead candidate targets chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease, using a proprietary drug discovery and development platform. Dimerix applies receptor-based science to create treatments that address unmet medical needs in complex diseases with few current therapeutic options. The company is involved in clinical trials to advance its drug candidates towards regulatory approval. The company is headquartered in Melbourne, Victoria, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage